FDA
-
-
-
-
-
-
-
Sight Sciences reports 24-month dry eye treatment durability data
-
-
-
-
-
-
-
Sight Sciences (SGHT) evaluating 2023 guidance due to "uncertain impact of reimbursement coverage for Surgical Glaucoma segment"
-
-
-
-
-
-
-
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
-
-
-
-
-
-
-
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCareĀ® Treatment Sustained Through 12 Months
-
-
-
-
-
-
-
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology
-
-
-
-
-
-
-
Sight Sciences (SGHT) Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNIĀ® Surgical System in Patients with Open Angle Glaucoma
-
-
-
-
-
-
-
Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting
-
329,975 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

